IRB Barcelona logo

News

Highlighting IRB Barcelona's impact on society

Laboratory of Molecular Biophysics News

Institutional
Dr. Eduard Batlle receives the Catalan National Research Award
Institutional
World Cancer Day 2024: Highlights of IRB Barcelona’s cancer research
Scientific
Hard to drug: Protein droplets reveal new ways to inhibit transcription factors in an aggressive form of prostate cancer
Scientific
A change in rigidity switches the function of protein condensates involved in sensing touch
Institutional
Nuage Therapeutics raises €12M in Seed Financing led by Sofinnova Partners and Asabys
Scientific
Researchers identify the mechanism that activates multiciliogenesis
Scientific
Protein droplets may cause many types of genetic disease
Media mentions
Una nueva herramienta para bloquear interacciones entre proteínas - BioTech
Scientific
A new tool to block protein-protein interactions
Institutional
The Spanish Association Against Cancer backs IRB Barcelona research with more than €3M
Innovation
Nuage Therapeutics, the spin-off from IRB Barcelona and ICREA, is launched with the support of Asabys
Innovation
The AECC funds research into new treatment for prostate cancer
Interaction of the androgen receptor and chaperone Hsp70 (in red) inside the cell. Blue indicates cell nuclei. Xavier Salvatella, IRB Barcelona.
Media mentions
A posible therapeutic target for Kennedy’s disease and prostate cancer
Interaction of the androgen receptor and chaperone Hsp70 (in red) inside the cell. Blue indicates cell nuclei. Xavier Salvatella, IRB Barcelona.
Scientific
Researchers at IRB Barcelona identify a possible therapeutic target for Kennedy´s disease and prostate cancer
The androgen receptor helix of polyglutamine becomes increasingly stable as the number (n) of glutamine amino acid residues increases.
Scientific
Researchers at IRB Barcelona discover the structural consequences of the mutation that causes Kennedy disease
Innovation
Researchers identify a molecule that halts and reverses neurodegeneration in Parkinson’s disease
The image shows interactions between the androgen receptor protein (AR) and the TFIIF protein in red. (Author: Paula Martínez-Cristóbal)
Scientific
Closing in on advanced prostate cancer
Xavier Salvatella (Photo: Battista/MinocriIRB Barcelona)
Media mentions
New line of attack against advanced prostate cancer in a study led by a Catalan scientist
CPEB4 liquid-like droplets in the cell cytoplasm (J. Guillén-Boixet, IRB Barcelona)
Scientific
Towards a better understanding of the puzzling “droplets” in the cell cytoplasm
Media mentions
The common enemy of Parkinson's, prostate cancer and Alzheimer's
Structure of the Androgen Receptor. NTD: N-terminal domain; DBD: DNA binding domain; LBD: Ligand binding domain. Numbers indicate the first and last aminoacids of the protein, and the domain limits.
Scientific
Researchers discover the hidden potential of disordered proteins
Protein Androgen Receptor forms aggregatesthat damage muscle and motor neuron cells in Kennedy's Disease (B. Eftekharzadeh, IRB Barcelona)
Scientific
Discovery of molecular protection linked to a degenerative neuromuscular disease
Media mentions
Treatment for late-stage prostate cancer patients: getting closer to a solution
Media mentions
Treatment for late-stage prostate cancer patients: getting closer to a solution
Institutional
IRB Barcelona’s “Meet Our Scientists” video series brings biomedicine closer to society
Media mentions
Supporting the excellence of outstanding students
Innovation
The biomedicine boom
Media mentions
Two million euros for a project against prostate cancer
In red, the domain of the androgen receptor protein where drugs to treat prostate cancer bind. In blue and black, parts of the protein where it might be feasible to direct new drugs (Author: Xavier Salvatella, IRB Barcelona)
Innovation
2M€ for studying protein motions and their implications for the treatment of prostate cancer
Innovation
Rare and orphan but not abandoned by science